US Patent 11389510 Controlled-release CNP agonists with low initial NPR-B activity
Patent 11389510 was granted and assigned to Ascendis Pharma on July, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 11 Sep, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 23 Apr, 2023
Golden AI
Edits on 3 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
113895100
Date of Patent
July 19, 2022
0Patent Application Number
160660580
Date Filed
January 5, 2017
0Patent Citations
Patent Primary Examiner
CPC Code
Edits on 1 Apr, 2023
Golden AI
Infobox
Patent Citations
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
113895100
Date of Patent
July 19, 2022
0Patent Application Number
160660580
Date Filed
January 5, 2017
0Patent Citations
Patent Primary Examiner
CPC Code
Edits on 20 Jul, 2022
Golden AI
Edits made to:
Infobox (+14 properties)
Article (+227 characters)
US Patent 11389510 Controlled-release CNP agonists with low initial NPR-B activity
Article
The present invention relates to a controlled-release CNP agonist from which CNP agonist is released with a release half-life of at least 6 hours under physiological conditions and which controlled-release CNP agonist has an EC
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11389510
Date of patent
July 19, 2022
Patent application number
16066058
Date Filed
January 5, 2017
Patent citations
Patent primary examiner
Find more entities like US Patent 11389510 Controlled-release CNP agonists with low initial NPR-B activity
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
